Equity Overview
Price & Market Data
Price: $2.48
Daily Change: +$0.07 / 2.82%
Daily Range: $2.36 - $2.53
Market Cap: $65,727,164
Daily Volume: 330,106
Performance Metrics
1 Week: 2.06%
1 Month: -13.89%
3 Months: -26.41%
6 Months: -0.40%
1 Year: 11.21%
YTD: -28.32%
Company Details
Employees: 8
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.